Subscribe To

Price Alert Latest News Economic Calendar News

BLTE / Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, will host a live webcast on Monday, April 3, 2023, at 4:30 p.m. Eastern time to discuss the Company's financial results for the full year ended December 31, 2022, and provide a general business update. The financial results will be issued in a press release on Friday, March 31, 2023. Read More

Demo Live Account See Partner Details

Content Topics

Belite

Host

Webcast

April

2023

Discuss

2022

Full

Year

Discuss 2022

Financial

Results

Stock

BLTE

Posted: Mar 31 2023, 12:57

Author Name: GlobeNewsWire

BLTE News

By Zacks Investment Research
August 21, 2023

Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why

Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is be

By Seeking Alpha
August 13, 2023

Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript

Belite Bio, Inc (NASDAQ:BLTE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive

By The Motley Fool
June 30, 2023

Why Shares of Belite Bio Soared This Week

Investors, seeing the 52-week low, saw a bargain in Belite Bio. The company doesn't have any revenue, but it has a promising eye disease therapy.

By Seeking Alpha
June 15, 2023

Belite Bio: Undercovered Eye Disease Company With Early Data

BLTE works with retinal disease patients. Their lead asset has positive phase 1 data. Their cash position and trial patient population are two worries

By Benzinga
June 9, 2023

Top 5 Health Care Stocks That Are Set To Fly In Q2 - ClearPoint Neuro (NASDAQ:CLPT), Belite Bio (NASDAQ:BLTE)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

By The Motley Fool
May 31, 2023

Why Shares of Belite Bio Are Slumping Wednesday

Belite Bio is a clinical-stage biopharmaceutical company focusing on rare eye diseases and other metabolic disorders. In the first quarter, the compan

By Seeking Alpha
May 14, 2023

Belite Bio, Inc (BLTE) Q1 2023 Earnings Call Transcript

Belite Bio, Inc (NASDAQ:BLTE ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Tom Lin - Chairman and Chief Executive Of

By GlobeNewsWire
May 10, 2023

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on adv

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.